MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. The trial evaluates the safety and efficacy of the combination of acimtamig (AFM13) with Artiva Biotherapeutics’ allogeneic NK cell AlloNK® in patients with R/R cHL.

See the original post here:
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin...

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID

See the rest here:
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic...

In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels

See the article here:
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become...

Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR) rates at week 961. The study compared the MMR rate of Scemblix to investigator-selected standard-of-care (SoC) tyrosine kinase inhibitors (TKIs) (imatinib, nilotinib, dasatinib and bosutinib) and to imatinib alone in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) at the week 96 evaluation, the study’s key secondary endpoints1. The longer-term results showed an increasing difference in Scemblix MMR rate vs. SoC, vs. imatinib and vs. 2G TKIs (nilotinib, dasatinib and bosutinib)1. Results were presented at the 66th American Society of Hematology Annual Meeting & Exposition (ASH)1.

See original here:
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Basel, 8 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, 7-10 December 2024 in San Diego, US. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results.1

Read the original post:
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –

Read the original post:
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

WATERTOWN, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive updated results from a Phase 1b trial of DISC-0974 in patients with myelofibrosis (MF) and anemia. The data, presented in an oral session at the 2024 American Society of Hematology (ASH) annual meeting in San Diego, CA, demonstrated that treatment with DISC-0974 results in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types.

Original post:
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th...

SHANGHAI, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Shanghai Zelixir Biotechnology Co., Ltd. ("Zelixir") today announced the official operation of its cutting-edge green manufacturing plant in Changzhou City, Jiangsu Province, China. This development signifies a major step forward in the convergence of Artificial Intelligence (AI) with synthetic biology, translating computational research into industrialization. Its product pipeline covers a range of areas including natural flavor, functional food and beauty ingredients.

View post:
Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney Function

Continue reading here:
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

MILAN, Dec. 09, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, presented preliminary safety data on the first two subjects dosed in the LUCE-1 trial, a Phase 1/2 open label clinical trial to assess safety and tolerability of AAVB-081, using the company’s proprietary dual hybrid gene therapy platform to deliver MYO7A protein in subjects with retinitis pigmentosa related to Usher Syndrome Type 1B (USH1B).

Read the rest here:
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related...

CITRYLL RAISES EUR 85 MILLION SERIES B TO ADVANCE NOVEL NET-TARGETING THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERS

Go here to read the rest:
Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders

CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, in New York, NY.

Read the original:
Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, today announced the Australian Patent Office has formally granted Recce a family three patent for its anti-infectives, with expiry in 2037.

Read the rest here:
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.

Originally posted here:
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global

See the article here:
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.

View original post here:
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented an ambitious development strategy to take advantage of the rapidly evolving phage therapy area.

Read more:
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –

More here:
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.

Read the original here:
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates.

Read the original here:
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates